Medical Developments International
Market Cap
AU$355.7m
Last Updated
2020/10/30 10:43 UTC
Data Sources
Company Financials +
Executive Summary
Medical Developments International Limited manufactures and distributes pharmaceutical and veterinary products, and medical devices. More Details
Rewards
Risk Analysis
Snowflake Analysis
High growth potential with excellent balance sheet.
Share Price & News
How has Medical Developments International's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MVP has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
-3.3%
MVP
-5.7%
AU Pharmaceuticals
-3.9%
AU Market
1 Year Return
-10.4%
MVP
-32.4%
AU Pharmaceuticals
-9.6%
AU Market
Return vs Industry: MVP exceeded the Australian Pharmaceuticals industry which returned -31.2% over the past year.
Return vs Market: MVP underperformed the Australian Market which returned -9.2% over the past year.
Shareholder returns
| MVP | Industry | Market | |
|---|---|---|---|
| 7 Day | -3.3% | -5.7% | -3.9% |
| 30 Day | 0.8% | -13.7% | 1.8% |
| 90 Day | -9.7% | -8.3% | 1.7% |
| 1 Year | -10.2%-10.4% | -32.3%-32.4% | -6.4%-9.6% |
| 3 Year | -13.4%-15.0% | -40.8%-41.7% | 12.3%-1.9% |
| 5 Year | 60.1%54.7% | -36.9%-40.4% | 40.0%11.3% |
Price Volatility Vs. Market
How volatile is Medical Developments International's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Update: Medical Developments International (ASX:MVP) Stock Gained 78% In The Last Five Years2 months ago | Simply Wall St
Estimating The Intrinsic Value Of Medical Developments International Limited (ASX:MVP)3 months ago | Simply Wall St
What Kind Of Investors Own Most Of Medical Developments International Limited (ASX:MVP)?Valuation
Is Medical Developments International undervalued compared to its fair value and its price relative to the market?
920.73x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: MVP (A$5.32) is trading above our estimate of fair value (A$0.35)
Significantly Below Fair Value: MVP is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: MVP is poor value based on its PE Ratio (920.7x) compared to the XO Pharmaceuticals industry average (38.5x).
PE vs Market: MVP is poor value based on its PE Ratio (920.7x) compared to the Australian market (20.8x).
Price to Earnings Growth Ratio
PEG Ratio: MVP is poor value based on its PEG Ratio (12.8x)
Price to Book Ratio
PB vs Industry: MVP is overvalued based on its PB Ratio (8.1x) compared to the AU Pharmaceuticals industry average (3.4x).
Next Steps
Future Growth
How is Medical Developments International forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
72.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MVP's forecast earnings growth (72.1% per year) is above the savings rate (2.3%).
Earnings vs Market: MVP's earnings (72.1% per year) are forecast to grow faster than the Australian market (18.3% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: MVP's revenue (28.2% per year) is forecast to grow faster than the Australian market (5% per year).
High Growth Revenue: MVP's revenue (28.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MVP's Return on Equity is forecast to be low in 3 years time (10.7%).
Next Steps
Past Performance
How has Medical Developments International performed over the past 5 years?
-18.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MVP has a high level of non-cash earnings.
Growing Profit Margin: MVP's current net profit margins (1.7%) are lower than last year (5%).
Past Earnings Growth Analysis
Earnings Trend: MVP's earnings have declined by 18.3% per year over the past 5 years.
Accelerating Growth: MVP's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: MVP had negative earnings growth (-63.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (117.8%).
Return on Equity
High ROE: MVP's Return on Equity (0.9%) is considered low.
Next Steps
Financial Health
How is Medical Developments International's financial position?
Financial Position Analysis
Short Term Liabilities: MVP's short term assets (A$26.0M) exceed its short term liabilities (A$8.2M).
Long Term Liabilities: MVP's short term assets (A$26.0M) do not cover its long term liabilities (A$33.2M).
Debt to Equity History and Analysis
Debt Level: MVP's debt to equity ratio (0.2%) is considered satisfactory.
Reducing Debt: MVP's debt to equity ratio has reduced from 6.4% to 0.2% over the past 5 years.
Debt Coverage: MVP's debt is well covered by operating cash flow (189%).
Interest Coverage: MVP earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Next Steps
Dividend
What is Medical Developments International current dividend yield, its reliability and sustainability?
0.56%
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MVP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MVP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MVP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MVP's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: MVP is not paying a notable dividend for the Australian market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MVP's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.3yrs
Average management tenure
CEO
R. Johnston
no data
Tenure
AU$60,000
Compensation
Mr. R. Max Johnston has been a Non-Executive Director of Medical Developments International Limited since November 05, 2012 and serves as its Acting Chief Executive Officer. He served as the President and ...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Acting CEO & Non-Executive Director | no data | AU$60.00k | 0.061% A$ 216.1k | |
| CFO & Company Secretary | 3yrs | AU$286.91k | no data | |
| Head of Sales & Marketing | 1.25yrs | no data | no data | |
| Head of Human Resources | 1.25yrs | no data | no data | |
| Chief Scientific Officer | 1.25yrs | no data | no data | |
| Head of Medical Affairs | 2.17yrs | no data | no data | |
| Head of Regulatory Affairs | 1.92yrs | no data | no data | |
| Head of Quality | 1.75yrs | no data | no data | |
| Head of Project Management Office | 1.25yrs | no data | no data | |
| Head of Production | 0.25yr | no data | no data | |
| Head of Europe | 0.17yr | no data | no data |
1.3yrs
Average Tenure
Experienced Management: MVP's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Acting CEO & Non-Executive Director | no data | AU$60.00k | 0.061% A$ 216.1k | |
| Non-Executive Director | no data | no data | no data | |
| Non-Executive Director | 5.83yrs | AU$60.00k | 0.40% A$ 1.4m | |
| Non Executive Chairman | 17.08yrs | AU$95.00k | 13.13% A$ 46.7m | |
| Non-Executive Director | 7.08yrs | AU$60.00k | 0.032% A$ 114.5k | |
| Non-Executive Director | 0.42yr | AU$5.00k | no data |
7.1yrs
Average Tenure
57yo
Average Age
Experienced Board: MVP's board of directors are considered experienced (7.1 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: MVP insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Medical Developments International Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Medical Developments International Limited
- Ticker: MVP
- Exchange: ASX
- Founded: 2003
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$355.679m
- Shares outstanding: 65.62m
- Website: https://medicaldev.com
Number of Employees
Location
- Medical Developments International Limited
- 4 Caribbean Drive
- Scoresby
- Victoria
- 3179
- Australia
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| MVP | ASX (Australian Securities Exchange) | Yes | Ordinary Shares | AU | AUD | Dec 2003 |
| MDDV.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Shares | US | USD | Dec 2003 |
| MVP | CHIA (Chi-X Australia) | Yes | Ordinary Shares | AU | AUD | Dec 2003 |
Biography
Medical Developments International Limited manufactures and distributes pharmaceutical and veterinary products, and medical devices. The company operates through three segments: Pharmaceuticals, Medical De ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/10/30 10:43 |
| End of Day Share Price | 2020/10/30 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2020/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.